Despite the treatments available for heart failure, hospitalization and mortality rates remain high. Optimized heart failure management is the key to improved patient outcomes and quality of life.1,3,4 With over 20 years of clinical evidence, Roche NT-proBNP provides support throughout the continuum of care in heart failure.5-6
| Characteristics | BNP | NT-proBNP 7 | NT-proBNP Advantages 7 |
|---|---|---|---|
| Half-life | 20 minutes |
60-120 minutes
|
Less prone to intra-day variability8 |
| Stability | Varies 4-24 hours at room temperature |
Up to 3 days at room temperature
|
Greater stability enables lab flexibility for outreach and add-on testing |
NT-proBNP assays, unlike BNP, are standardized across manufacturers. In the Emergency Department and inpatient and outpatient settings, consistent results allow for more confidence in heart failure management.
NT-proBNP delivers confidence when managing patients across the heart failure spectrum.
Please submit your information in the following form to be contacted by a Roche representative with more details.
Some biomarkers are affected by certain medications. For instance, if a patient is taking an ARNI (angiotensin receptor-neprilysin inhibitor), BNP levels will appear elevated, potentially leading to erroneous treatment. Using NT-proBNP, levels of which are not affected by neprilysin, you can ensure you will have the most accurate clinical picture to provide the best patient care.8
References
